Wuhan, China

Xiaoling Dun

This inventor holds 1 USPTO granted patent. Top assignee: Chinese Academy of Agricultural Sciences. Active years: 2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Xiaoling Dun. Retrieved from https://idiyas.com/inventor/xiaoling-dun

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

Average Co-Inventor Count = 1.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Innovations by Xiaoling Dun in Agricultural Science.

Introduction

Xiaoling Dun is a prominent inventor based in Wuhan, China. She has made significant contributions to agricultural science, particularly in the area of crop disease resistance. Her work focuses on improving the resilience of cruciferous crops against clubroot disease.

Latest Patents

Xiaoling Dun holds a patent titled "Use of beta-1,3-glucan synthase like 5 in improving clubroot disease resistance and related product development in cruciferous crops." This patent highlights her innovative approach to enhancing crop health and productivity.

Career Highlights

Dun is affiliated with the Chinese Academy of Agricultural Sciences, where she conducts her research. Her work has been instrumental in advancing agricultural practices and developing solutions to combat plant diseases.

Collaborations

Xiaoling has collaborated with notable colleagues, including Lijiang Liu and Shengyi Liu. These partnerships have further enriched her research and contributed to the success of her projects.

Conclusion

Xiaoling Dun's innovative work in agricultural science exemplifies the importance of research in enhancing crop resilience. Her contributions are vital for the future of sustainable agriculture.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…